Complement C1 Inhibitor Protein clinical trials
Also written C1 Esterase Inhibitor.
Counted the way a researcher would: Complement C1 Inhibitor Protein with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Complement C1 Inhibitor Protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Complement C1 Inhibitor Protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Jul 2014 · Ruconest · BLA 125495 (FDA, Purple Book)
- European Union
- 28 Oct 2010 · Ruconest · EMEA/H/C/001223 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2005 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 11
Shire (5) · CSL Behring (4) · Pharming Technologies B.V. (4) · Radboud University Medical Center (2) · Universitaire Ziekenhuizen KU Leuven (1) · IMMUNOe Research Centers (1) · NYU Langone Health (1) · Cedars-Sinai Medical Center (1)
Often tested with
Tested in the same studies.
Conestat alfa (4) · C1 esterase inhibitor (human) (4) · Antithrombin-III (1) · Antithrombin III (1) · Infliximab (1) · Apotransferrin (1) · Glutathione (1) · Melatonin (1)
Related medicines
As reviewed, each with the page that says it.
- Conestat alfa is a recombinant medicine of it, counted here with related medicines source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Complement C1 Inhibitor Protein.
- Mar 2027Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)Phase 2 · Haaglanden Medical Centre
Studies
Open first, then newest update. How each study uses Complement C1 Inhibitor Protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)RecruitingPhase 2Haaglanden Medical CentreNCT06359782Written as C1 Esterase Inhibitor Injection [Cinryze]
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)CompletedPhase 2Universitaire Ziekenhuizen KU LeuvenNCT02251041Written as C1-Inhibitor
- Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsTerminatedPhase 3CSL BehringNCT03221842Written as C1-esterase inhibitor
- C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT00289211Written as C1 esterase inhibitor [human] (C1INH-nf)
- C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT01005888Written as C1 esterase inhibitor [human] (C1INH-nf)
- Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT00438815Written as C1 esterase inhibitor [human] (C1INH-nf)
- Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT00462709Written as C1 esterase inhibitor [human] (C1INH-nf)
- Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema SubjectsCompletedPhase 1ShireNCT00432510Written as C1 esterase inhibitor [human] (C1INH-nf)
- A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG InfusionsCompletedPhase 4IMMUNOe Research CentersNCT03576469Written as C1-esterase inhibitor [recombinant] (C1-INH-R)
- Research Into the Effect of a Clot-dissolving Agent and Its InhibitorTerminatedEarly Phase 1TSI, LLCNCT01694381Written as C1-inhibitor
- C1-inhibitor in Allergic ASThma PatientsTerminatedPhase 4T. van der PollNCT03051698Written as C1-inhibitor
- C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft RejectionCompletedPhase 2NYU Langone HealthNCT02936479Written as C1-INH (Berinert)
- A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedPhase 3CSL BehringNCT02316353Written as C1-esterase inhibitor
- A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedPhase 2Pharming Technologies B.V.NCT00851409Written as Recombinant Human C1 Inhibitor
- C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRICompletedPhase 1/2Cedars-Sinai Medical CenterNCT02134314Written as C1 Esterase Inhibitor
- A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedPhase 2Pharming Technologies B.V.NCT02247739Written as Recombinant human C1 inhibitor
- Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent RejectionCompletedPhase 1/2Stanley Jordan, MDNCT01134510Written as C1 Esterase Inhibitor
- C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CompletedPhase 3CSL BehringNCT00292981Written as C1 Esterase Inhibitor
- Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCompletedPhase 2/3CSL BehringNCT00168103Written as C1 Esterase Inhibitor
- Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic FractureTerminatedPhase 3UMC UtrechtNCT01275976Written as C1-esterase inhibitor
See all 26 studies that test Complement C1 Inhibitor Protein →
Codes
What other systems call Complement C1 Inhibitor Protein · ClinicalTrials.gg INT008866
- MeSH (NLM) D050718Complement C1 Inhibitor ProteinOne source ClinicalTrials.gov
- RxNorm 1599831One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D050718 | Complement C1 Inhibitor Protein | One source ClinicalTrials.gov |
| RxNorm | 1599831 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.